The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy

References

• Mohr P, Pecenák J, Svestka J, et al. Treatment of acute agitation in psychotic disorders. Neuro Endocrinol Lett. 2005;26:327–335.
   PubMed Web of Science ®Google Scholar
• Vieta E, Garriga M, Cardete L, et al. Protocol for the management of psychiatric patients with psychomotor agitation. BMC Psychiatry. 2017;17:328.
   PubMed Web of Science ®Google Scholar
• Correll CU, Yu X, Xiang Y, et al. Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting. Ann Clin Psychiatry. 2017;29:92–107.
   PubMed Web of Science ®Google Scholar
• Hankin CS, Bronstone A, Koran LM. Agitation in the inpatient psychiatric setting. J Psychiatr Pract. 2011;17:170–185.
   PubMed Web of Science ®Google Scholar
• Powell G, Caan W, Crowe M. What events precede violent incidents in psychiatric hospitals? Br J Psychiatry. 1994;165:107–112.
   PubMed Web of Science ®Google Scholar
• Brieden T, Ujeyl M, Naber D. Psychopharmacological treatment of aggression in schizophrenic patients. Pharmacopsychiatry. 2002;35:83–89.
   PubMed Web of Science ®Google Scholar
• Zhou J-S, Zhong B-L, Xiang Y-T, et al. Prevalence of aggression in hospitalized patients with schizophrenia in China: A meta-analysis. Asia-Pac Psychiatry. 2016;8:60–69.
   PubMed Web of Science ®Google Scholar
• Cornaggia CM, Beghi M, Pavone F, et al. Aggression in psychiatry wards: A systematic review. Psychiatry Res. 2011;189:10–20.
   PubMed Web of Science ®Google Scholar
• NICE. Overview | violence and aggression: short-term management in mental health, health and community settings | guidance | NICE. Br Psychol Soc. 2015;10. [cited 2019 Oct 1]. Available from: https://www.nice.org.uk/guidance/ng10
   Google Scholar
• Allen MH, Currier GW, Hughes DH, et al. The expert consensus guideline series. Treatment of behavioral emergencies. Postgrad Med. 2001;1–88(quiz):89–90.
   Google Scholar
• Garriga M, Pacchiarotti I, Kasper S, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016;17:86–128.
   PubMed Web of Science ®Google Scholar
• Richmond JS, Berlin JS, Fishkind AB, et al. Verbal de-escalation of the agitated patient: consensus statement of the American association for emergency psychiatry project BETA de-escalation workgroup. West J Emerg Med. 2012;13:17–25.
   PubMedGoogle Scholar
• Swift R, Harrigan E, Cappelleri J, et al. Validation of the behavioural activity rating scale (BARS)TM: a novel measure of activity in agitated patients. J Psychiatr Res. 2002;36:87–95.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (panss) for schizophrenia. Schizophr Bull. 1987;13:261–276.
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Brown E, Baker RW, et al. An excitement subscale of the positive and negative syndrome scale. An Excitement Subscale Of The Positive and Negative Syndrome Scale. an Excitement Subscale Of The Positive and Negative Syndrome Scale. Schizophr Res. 2004;68:331-337.
   Google Scholar
• Montoya A, Valladares A, Lizán L, et al. Validation of the excited component of the positive and negative syndrome scale (PANSSEC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes. 2011;9:18.
   PubMed Web of Science ®Google Scholar
• Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med. 2003;21:192–198.
   PubMed Web of Science ®Google Scholar
• Yu X, Correll CU, Xiang Y-T, et al. Efficacy of atypical antipsychotics in the management of acute agitation and aggression in hospitalized patients with schizophrenia or bipolar disorder: results from a systematic review. Shanghai Arch Psychiatry. 2016;28:241–252.
   PubMedGoogle Scholar
• Faden J, Citrome L. Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Neuropsychiatr Dis Treat. 2019;15:2273–2283.
   PubMed Web of Science ®Google Scholar
• Bak M, Weltens I, Bervoets C, et al. The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis. Eur Psychiatry. 2019;57:78–100.
   PubMed Web of Science ®Google Scholar
• Griffin CE, Kaye AM, Bueno FR, et al. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13:214–223.
   PubMedGoogle Scholar
• West-Ward Pharmaceuticals Corp. ATIVAN- lorazepam injection. Product label. Revised 04/2017. [cited 2019 Oct 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018140s028lbl.pdf
   Google Scholar
• Valeant Pharmaceuticals International, Inc. Ativan C-IV (lorazepam) tablets. Product label. Revised 12/2016. [cited 2019 Oct 15]. Available from: https://www.bauschhealth.com/Portals/25/Pdf/PI/Ativan-PI.pdf
   Google Scholar
• Hospira Inc. MIDAZOLAM HYDROCHLORIDE- midazolam hydrochloride injection, solution. Product label. Revised 07/2019. [cited 2019 Oct 13]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1abda8b8-48a8-4995-af86-39220d1aa240
   Google Scholar
• Zaman H, Sampson S, Beck A, et al. Benzodiazepines for psychosis-induced aggression or agitation. Schizophr Bull. 2018;44:966–969.
   PubMed Web of Science ®Google Scholar
• Kousgaard S, Licht R, Nielsen R. Effects of intramuscular midazolam and lorazepam on acute agitation in non-elderly subjects – A systematic review. Pharmacopsychiatry. 2017;50:129–135.
   PubMed Web of Science ®Google Scholar
• Mantovani C, Labate CM, Sponholz A, et al. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions. J Clin Psychopharmacol. 2013;33:306–312.
   PubMed Web of Science ®Google Scholar
• Dold M, Li C, Tardy M, et al. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2012;11:CD006391.
   PubMedGoogle Scholar
• Rasmussen SA, Mazurek MF, Rosebush PI. Catatonia: our current understanding of its diagnosis, treatment and pathophysiology. World J Psychiatry. 2016;6:391–398.
   PubMed Web of Science ®Google Scholar
• Jones KA, Nielsen S, Bruno R, et al. Benzodiazepines their role in aggression and why GPs should prescribe with caution. Aust Fam Physician. 2011;40:862–865.
   PubMed Web of Science ®Google Scholar
• Donlon PT, Meadow A, Tupin JP, et al. High vs standard dosage fluphenazine HCL in acute schizophrenia. J Clin Psychiatry. 1978;39:800–804.
   PubMed Web of Science ®Google Scholar
• Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database Syst Rev. 2010;(4):CD007445.
   PubMed Web of Science ®Google Scholar
• Khokhar MA, Rathbone J. Droperidol for psychosis-induced aggression or agitation. Cochrane Database Syst Rev. 2016;12:CD002830.
   PubMedGoogle Scholar
• Janssen Pharmaceuticals. Inc. HALDOL brand of haloperidol injection (For immediate release). (Product label). Revised 03/2019. [cited 2020 Jan 27]. Available from: http://www.janssenlabels.com/packageinsert/product-monograph/prescribing-information/HALDOL-pi.pdf
   Google Scholar
• Zun LS. Evidence-based review of pharmacotherapy for acute agitation. Part 2: safety. J Emerg Med. 2018;54:522–532.
   PubMed Web of Science ®Google Scholar
• Tyler MW, Zaldivar-Diez J, Haggarty SJ. Classics in chemical neuroscience: haloperidol. ACS Chem Neurosci. 2017;8:444–453.
   PubMed Web of Science ®Google Scholar
• Ostinelli EG, Brooke-Powney MJ, Li X, et al. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev.2017;7:CD009377.
   Google Scholar
• Galen. ADASUVE (loxapine) inhalation powder, for oral inhalation use. Product label. Revised 02/2017. [cited 2019 Oct 7]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528
   Google Scholar
• Ferrer Internacional. ADASUVE (loxapine) inhalation powder. Product label. [cited 2020 Jan 20]. Available from: https://www.ema.europa.eu/en/documents/product-information/adasuve-epar-product-information_en.pdf
   Google Scholar
• Kwentus J, Riesenberg RA, Marandi M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012;14:31–40.
   PubMed Web of Science ®Google Scholar
• Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia. J Clin Psychiatry. 2011;72:1313–1321.
   PubMed Web of Science ®Google Scholar
• Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011;198:51–58.
   PubMed Web of Science ®Google Scholar
• San L, Estrada G, Oudovenko N, et al. PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. Eur Neuropsychopharmacol. 2018;28:710–718.
   PubMed Web of Science ®Google Scholar
• McDowell M, Nitti K, Kulstad E, et al. Clinical outcomes in patients taking inhaled loxapine, haloperidol, or ziprasidone in the emergency department. Clin Neuropharmacol. 2019;42:23–26.
   PubMed Web of Science ®Google Scholar
• Otsuka Pharmaceutical Co. ABILIFY (aripiprazole) tablets, ABILIFY DISCMELT (aripiprazole) orally disintegrating tablets, ABILIFY (aripiprazole) oral solution, ABILIFY (aripiprazole) injection for intramuscular use only. Product label. Revised 08/2019. [cited 2020 Jan 20]. Available from: www.fda.gov/medwatch
   Google Scholar
• Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder. J Clin Psychopharmacol. 2007;27:171–176.
   PubMed Web of Science ®Google Scholar
• Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68:111–119.
   PubMed Web of Science ®Google Scholar
• Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: A double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl). 2006;188:281–292.
   PubMed Web of Science ®Google Scholar
• Ostinelli EG, Jajawi S, Spyridi S, et al. Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev. 2018;1:CD008074.
   Web of Science ®Google Scholar
• Pfizer. GEODON-ziprasidone hydrochloride capsule, GEODON-ziprasidone mesylate injection, powder, lyophilized, for solution. Product label. Revised 11/2018. [cited 2019 Oct 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020825s053,020919s040,s021483s013lbl.pdf
   Google Scholar
• Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001;62:12–18.
   PubMed Web of Science ®Google Scholar
• Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl). 2001;155:128–134.
   PubMed Web of Science ®Google Scholar
• Miceli JJ, Tensfeldt TG, Shiovitz T, et al. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Clin Ther. 2010;32:472–491.
   PubMed Web of Science ®Google Scholar
• Allergan. Saphris (asenapine) sublingual tablets. Product label. Revised 02/2017. [cited 2019 Oct 13]. Available from: https://www.allergan.com/assets/pdf/saphris_pi
   Google Scholar
• Pratts M, Citrome L, Grant W, et al. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand. 2014;130:61–68.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals. RISPERDAL (risperidone) tablets, RISPERDAL (risperidone) oral solution, RISPERDAL M-TAB (risperidone)orally disintegrating tablets. (Product label). Revised 01/2019. [cited 2019 Oct 13]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribinginformation/RISPERDAL-pi.pdf
   Google Scholar
• Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001;62:153–157.
   PubMed Web of Science ®Google Scholar
• Currier GW, Chou JC-Y, Feifel D, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry. 2004;65:386–394.
   PubMed Web of Science ®Google Scholar
• Ostinelli EG, Hussein M, Ahmed U, et al. Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev. 2018;4:CD009412.
   PubMedGoogle Scholar
• Precedex (Dexmedetomidine) [package insert]. Lake Forest (IL): Hospira Inc.; 2018. [cited 2019 Sept 26]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=548a88c0-afda-427e-75ac-5af0cfa2224c&type=display
   Google Scholar
• Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56:893–913.
   PubMed Web of Science ®Google Scholar
• Afonso J, Reis F. Dexmedetomidine: current role in anesthesia and intensive care. Rev Bras Anestesiol. 2012;62:125–133.
   Web of Science ®Google Scholar
• Doze V, Chen BX, Li Z, et al. Pharmacologic characterization of the receptor mediating the hypnotic action of dexmedetomidine. Acta Vet Scand Suppl. 1989;85:61–64.
   PubMedGoogle Scholar
• Doze VA, Chen B-X, Maze M. Dexmedetomidine produces a hypnotic–anesthetic action in rats via activation of central alpha-2 adrenoceptors. Anesthesiology. 1989;71:75–79.
   PubMed Web of Science ®Google Scholar
• Chrysostomou C, Schmitt CG. Dexmedetomidine: sedation, analgesia and beyond. Expert Opin Drug Metab Toxicol. 2008;4:619–627.
   PubMed Web of Science ®Google Scholar
• Anttila M, Penttilä J, Helminen A, et al. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br J Clin Pharmacol. 2003;56:691–693.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu Y, Miao S, et al. Effects of peri-operative intravenous administration of dexmedetomidine on emergence agitation after general anesthesia in adults: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2019;13:2853–2864.
   PubMed Web of Science ®Google Scholar
• Dahmani S, Stany I, Brasher C, et al. Pharmacological prevention of sevoflurane- and desflurane-related emergence agitation in children: a meta-analysis of published studies. Br J Anaesth. 2010;104:216–223.
   PubMed Web of Science ®Google Scholar
• FitzSimons J, Bonanno LS, Pierce S, et al. Effectiveness of preoperative intranasal dexmedetomidine, compared with oral midazolam, for the prevention of emergence delirium in the pediatric patient undergoing general anesthesia. JBI Database Syst Rev Implement Rep. 2017;15:1934–1951.
   PubMedGoogle Scholar
• Munk L, Andersen G, Møller AM. Post-anaesthetic emergence delirium in adults: incidence, predictors and consequences. Acta Anaesthesiol Scand. 2016;60:1059–1066.
   PubMed Web of Science ®Google Scholar
• Scheinin H, Aantaa R, Anttila M, et al. Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers. Anesthesiology. 1998;89:574–584.
   PubMed Web of Science ®Google Scholar
• Shrewsbury S, Swardstrom M, Satterly K, et al. SNAP 101: Randomized, Crossover, Active/Placebo-Controlled, Safety and Pharmacokinetic/Pharmacodynamic Study of 3 Ascending Doses of POD® Olanzapine. Poster presentation P8-162. Presented at the American Psychiatric Association (APA) Annual Meeting, May 18–22, 2019, San Francisco, CA
   Google Scholar
• Eli Lilly and Company. ZYPREXA - olanzapine tablet, ZYPREXA ZYDIS - olanzapine tablet, orally disintegrating, ZYPREXA INTRAMUSCULAR - olanzapine injection, powder, for solution. Product label. Revised 10/2019. [cited 2020 Jan 26]. Available from: https://pi.lilly.com/us/zyprexa-pi.pdf
   Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177–193.
   PubMed Web of Science ®Google Scholar
• Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59:441–448.
   PubMed Web of Science ®Google Scholar
• Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001;158:1149–1151.
   PubMed Web of Science ®Google Scholar
• Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001;21:389–397.
   PubMed Web of Science ®Google Scholar
• Katagiri H, Fujikoshi S, Suzuki T, et al. A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. BMC Psychiatry. 2013;13:20.
   PubMed Web of Science ®Google Scholar
• Zun LS. Evidence-based review of pharmacotherapy for acute agitation. Part 1: onset of efficacy. J Emerg Med. 2018;54:364–374.
   PubMed Web of Science ®Google Scholar
• Citrome L, McEvoy JP, Todtenkopf MS, et al. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatr Dis Treat. 2019;15:2559–2569.
   PubMed Web of Science ®Google Scholar
• Williams AM. Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness. Ment Heal Clin. 2018;8:208–213.
   PubMedGoogle Scholar